http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2012113839-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P33-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J5-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J7-008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P33-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-352 |
| filingDate | 2012-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2012113839-A |
| titleOfInvention | CRYSTALLINE SOLVATE FORM OF CORTEXOLON-17ALPA-PROPIONATE AND METHOD FOR ITS PRODUCTION |
| abstract | 1. The crystalline solvate form IV of cortexolone-17α-propionate, characterized by DRL, as shown in Fig.28, and / or IR, as shown in Fig.29.2. The crystalline form according to claim 1 is effective for the treatment of pathologies of the genitourinary system, endocrine system, skin and / or skin appendages. The crystalline form according to claim 2 for the treatment of acne, seborrheic dermatitis, androgenetic alopecia, hirsutism, benign prostatic hyperplasia, forms of prostate cancer, male contraception, polycystic ovary syndrome, premature puberty syndrome and the regulation of aggressive or aberrant sexual behavior. A pharmaceutical composition for treating pathologies of the genitourinary system, endocrine system, skin and / or skin appendages, containing the crystalline solvate form according to claim 1 in combination with at least one physiologically acceptable excipient. 5. The pharmaceutical composition according to claim 4 for the treatment of acne, seborrheic dermatitis, androgenetic alopecia, hirsutism, benign prostatic hyperplasia, forms of prostate cancer, male contraception, polycystic ovary syndrome, premature puberty syndrome and the regulation of aggressive or aberrant sexual behavior. The pharmaceutical composition according to claim 4 or 5 in solid, semi-solid, pasty or liquid form. The composition according to claim 6 in the form of a tablet, capsule, powder, granule, suspension, emulsion, solution, cream, gel, ointment, lotion or paste. A method for producing crystalline solvate form IV of cortexolone-17α-propionate according to claim 1, comprising crystallizing cortexolone-17α-propionate from an organic solvent / water mixture. C |
| priorityDate | 2007-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 40.